- Tivic Health (TIVC, Financial) has completed an Optimization Study for its non-invasive cervical vagus nerve stimulation (ncVNS) device.
- The study aims to enhance therapeutic efficacy through personalized stimulation parameters.
- The global VNS market is projected to grow significantly, offering a substantial opportunity for Tivic's innovations.
Tivic Health Systems, Inc. (TIVC), a company focused on developing treatments that stimulate immune pathways, has successfully completed all study visits in its Optimization Study for a non-invasive cervical vagus nerve stimulation (ncVNS) device. Conducted by The Feinstein Institute of Bioelectronic Medicine, the study aimed at identifying optimal device parameters such as frequency, amplitude, electrode positioning, and personalization, which are critical for influencing the autonomic nervous system function.
The initial findings highlight the significance of personalized treatment for therapeutic efficacy. Tivic's innovative approach towards enhancing vagus nerve stimulation could potentially lead to differentiated treatments for numerous diseases. The company plans to release detailed study results later this year, which are expected to inform its upcoming Phase I clinical trial.
Commenting on the completion of the study, Tivic Health's CEO, Jennifer Ernst, expressed confidence in their bioelectronic approach to developing vagus nerve stimulation therapies. The company is poised to address unmet clinical needs across large patient populations with its novel treatments.
The market for vagus nerve stimulation is robust, with Polaris Market Research predicting an increase from $8.59 billion in 2021 to $21.3 billion by 2030, representing a compound annual growth rate (CAGR) of 10.6%. Moreover, the segment of peripheral nerve stimulation, targeted by Tivic Health, is anticipated to grow at an even faster rate of 35% CAGR, supported by forecasts from IDTechEx.
Tivic Health, headquartered in Fremont, California, continues to leverage its advanced bioelectronic technology platforms, such as the FDA-approved ClearUP™ device, to develop personalized non-invasive medical devices aimed at modulating critical pathways in prevalent diseases.
